NO308509B1 - FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse - Google Patents

FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse Download PDF

Info

Publication number
NO308509B1
NO308509B1 NO923542A NO923542A NO308509B1 NO 308509 B1 NO308509 B1 NO 308509B1 NO 923542 A NO923542 A NO 923542A NO 923542 A NO923542 A NO 923542A NO 308509 B1 NO308509 B1 NO 308509B1
Authority
NO
Norway
Prior art keywords
cells
idiotype
making
protein
dendritic cells
Prior art date
Application number
NO923542A
Other languages
English (en)
Norwegian (no)
Other versions
NO923542D0 (no
NO923542L (no
Inventor
Heribert Bohlen
Jacques Urbain
Benjamin Van Camp
Kristiaan Thielemans
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23960532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308509(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of NO923542D0 publication Critical patent/NO923542D0/no
Publication of NO923542L publication Critical patent/NO923542L/no
Publication of NO308509B1 publication Critical patent/NO308509B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO923542A 1990-03-14 1992-09-11 FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse NO308509B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/493,511 US20030072751A1 (en) 1990-03-14 1990-03-14 Idiotypic vaccination against b cell lymphoma
PCT/US1991/001683 WO1991013632A1 (en) 1990-03-14 1991-03-13 Idiotypic vaccination against b cell lymphoma

Publications (3)

Publication Number Publication Date
NO923542D0 NO923542D0 (no) 1992-09-11
NO923542L NO923542L (no) 1992-09-11
NO308509B1 true NO308509B1 (no) 2000-09-25

Family

ID=23960532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923542A NO308509B1 (no) 1990-03-14 1992-09-11 FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse

Country Status (12)

Country Link
US (1) US20030072751A1 (de)
EP (1) EP0521897B1 (de)
JP (1) JP2735947B2 (de)
AT (1) ATE124265T1 (de)
AU (1) AU645552B2 (de)
CA (1) CA2078235C (de)
DE (1) DE69110877T2 (de)
DK (1) DK0521897T3 (de)
ES (1) ES2074268T3 (de)
FI (1) FI105452B (de)
NO (1) NO308509B1 (de)
WO (1) WO1991013632A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
DE69333433T2 (de) * 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
EP0651653B1 (de) * 1992-07-22 2004-03-10 The Trustees Of Princeton University P53 impfstoff
JPH08503603A (ja) * 1992-08-21 1996-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ 新規のｂリンパ腫細胞株および抗原
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
EP0692973A1 (de) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide beschichtete zellen als immunogene
PT765386E (pt) * 1994-06-14 2015-02-06 Univ Leland Stanford Junior Processos para a activação in vivo de células t, através de células dendríticas pulsadas com antigénio
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
AU2872199A (en) 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
EP1176986B1 (de) 1999-04-20 2018-07-04 Yale University Differenzierung von monozyten in funktionale dentritische zellen
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Also Published As

Publication number Publication date
AU645552B2 (en) 1994-01-20
NO923542D0 (no) 1992-09-11
JPH05507905A (ja) 1993-11-11
DE69110877D1 (de) 1995-08-03
NO923542L (no) 1992-09-11
CA2078235A1 (en) 1991-09-15
AU7488691A (en) 1991-10-10
ES2074268T3 (es) 1995-09-01
FI924082A0 (fi) 1992-09-11
FI924082L (fi) 1992-09-11
WO1991013632A1 (en) 1991-09-19
ATE124265T1 (de) 1995-07-15
JP2735947B2 (ja) 1998-04-02
FI105452B (fi) 2000-08-31
CA2078235C (en) 2004-01-20
EP0521897A1 (de) 1993-01-13
EP0521897B1 (de) 1995-06-28
DK0521897T3 (da) 1995-11-13
US20030072751A1 (en) 2003-04-17
DE69110877T2 (de) 1995-11-16

Similar Documents

Publication Publication Date Title
NO308509B1 (no) FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse
Tada et al. Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia-and Ia+ helper T cells.
Leclerc et al. A synthetic vaccine constructed by copolymerization of B and T cell determinants
US20090117135A1 (en) Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies
Taniguchi et al. Cellular consequences in the suppression of antibody response by the antigen-specific T-cell factor.
Abdel-Motal et al. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody
NO319013B1 (no) Vaksine omfattende type I overflateantigener fra Staphylococcus epidermidis, samt hyperimmune globuliner og antistoff rettet mot type I-overflateantigenet.
CA2027317A1 (en) Vaccine composition with non-immunosuppressive t-cell epitope component
Bot et al. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer
US5989542A (en) Capsular polysaccharides from enterococci
Ramalho‐Pinto et al. Murine Schistosomiasis mansoni: anti‐schistosomula antibodies and the IgG subclasses involved in the complement‐and eosinophilmediated killing of schistosomula in vitro
Francotte et al. Enhancement of antibody response by mouse dendritic cells pulsed with tobacco mosaic virus or with rabbit antiidiotypic antibodies raised against a private rabbit idiotype.
Dorfman The optimal technological approach to the development of human hybridomas
US4545986A (en) Timothy grass antigen specific anti-idiotypic antibodies
Hendriksen et al. Production of polyclonal and monoclonal antibodies
Prager et al. Immunological stimulation with modified lymphoma cells in a minimally responsive tumor-host system
US20040009195A1 (en) Modified sialic acid vaccines
CA2176738C (en) Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
Cohen et al. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice
US20020122809A1 (en) Capsular polysaccharides from enterococci
Kodama et al. Induction of IgM memory with RNA from the spleens of immunized mice
Ding et al. Activation of helper T cells by immune complexes
RU2063245C1 (ru) Способ получения антител для производства диагностических препаратов вируса клещевого энцефалита
EP1474682A2 (de) Produktion von menschlichen antikörpern in immundefizienten, nicht-menschlichen säugerwirten
Frey Study of immune response to tumors in the rat

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees